Literature DB >> 302170

The mechanism of action of cyclophosphamide on the nephritis of (NZB x NZW)F1 hybrid mice.

E R Hurd, M Ziff.   

Abstract

The effects of cyclophosphamide an antinuclear antibody levels, immune complex deposition in renal glomeruli, glomerular cell proliferation and glomerulosclerosis in the (NZB x NZW)F1 hybrid mouse have been investigated in order to better understand the mechanism of action of this drug on nephritis. Five groups of mice were injected daily with this agent (15 mg/kg) by the i.p. route over a 2-month period. Treatment periods began at 1, 3, 5, 7 and 9 months. Each group was killed at the end of the treatment period. During the last week [3H]Tdr(1 mu Ci/g) was injected daily i.p. Immune complex deposition was measured by quantification of glomerular immunofluorescent staining in both capillary loops and mesangium. Glomerular cell proliferation was quantified by measurement of the number of glomerular cells which incorporated [3H]Tdr during in vivo labelling. The number of [3H]Tdr-labelled cells in each of 100 glomeruli was counted using kidney autoradiographs of whole kidney slices. This technique provided a very reproducible and quantitative index of glomerular cell proliferation. Glomerulosclerosis was measured by determining percentage of PAS-positive material in each of 100 counted glomeruli. Immune complex deposition in the kidney preceded the glomerular cell proliferation. The proliferation reached a peak at 9 months of age. Glomerulosclerosis gradually increased with age until the animal's death. Cyclophosphamide significantly decreased antinuclear antibody levels, glomerular cell proliferation, and immunoglobulin staining in the glomeruli. Progression of glomerulosclerosis was significantly arrested. The present findings demonstrate a very significant effect of cyclophosphamide on three important pathological changes which occur in the nephritis of the (NZB x NZW)F1 hybrid mouse and provide information about possible mechanisms underlying these changes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 302170      PMCID: PMC1541054     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Effect of cyclophosphoramide, 6-mercaptopurine, actinomycin D and vincaleukoblastine on the acquisition of delayed hypersensitivity (DNCB) contact dermatitis) in the guinea-pig.

Authors:  H C MAGUIRE; H I MAIBACH
Journal:  J Invest Dermatol       Date:  1961-11       Impact factor: 8.551

2.  Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice.

Authors:  B H Hahn; L Knotts; M Ng; T R Hamilton
Journal:  Arthritis Rheum       Date:  1975 Mar-Apr

3.  Direct immunofluorescent identification of respiratory syncytial virus in throat swabs from children with respiratory illness.

Authors:  K G Gray; D E MacFarlane; R G Sommerville
Journal:  Lancet       Date:  1968-03-02       Impact factor: 79.321

4.  Cyclophosphamide in lupus nephritis: a controlled trial.

Authors:  A D Steinberg; H B Kaltreider; P J Staples; E J Goetzl; N Talal; J L Decker
Journal:  Ann Intern Med       Date:  1971-08       Impact factor: 25.391

5.  Differential effects of 6-mercaptopurine and cyclophosphamide on autoimmune phenomena in NZB mice.

Authors:  E Lemmel; E R Hurd; M Ziff
Journal:  Clin Exp Immunol       Date:  1971-02       Impact factor: 4.330

6.  Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis.

Authors:  T P Casey
Journal:  Blood       Date:  1968-09       Impact factor: 22.113

7.  Cyclophosphamide treatment of mouse systemic lupus erythematosus.

Authors:  R E Horowitz; E L Dubois; J Weiner; L Strain
Journal:  Lab Invest       Date:  1969-09       Impact factor: 5.662

8.  Comparison of the effects of two cytotoxic drugs and of antilymphocytic serum on immune and non-immune inflammation in experimental animals.

Authors:  R Arinoviche; G Loewi
Journal:  Ann Rheum Dis       Date:  1970-01       Impact factor: 19.103

9.  Quantitative studies of immunoglobulin deposition in the kidney, glomerular cell proliferation and glomerulosclerosis in NZB/NZW F1 hybrid mice.

Authors:  E R Hurd; M Ziff
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

  9 in total
  6 in total

Review 1.  Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.

Authors:  Laurie S Davis; Andreas M Reimold
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

2.  Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

Authors:  A Tarkowski; K Gunnarsson; T Stålhandske
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

3.  Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.

Authors:  M Shiraki; M Fujiwara; S Tomura
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

4.  Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice.

Authors:  R Jonsson; A Tarkowski; K Bäckman
Journal:  Agents Actions       Date:  1988-12

5.  Effects of pulse cyclophosphamide on NZB/W disease.

Authors:  D Chia; L Levy; E V Barnett; W H Carnes
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

6.  Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.

Authors:  Victoria L Wolf; Erin B Taylor; Michael J Ryan
Journal:  Physiol Rep       Date:  2019-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.